oxytocin intranasal (OPN-300) / Paratek Pharmaceuticals - LARVOL DELTA

Paratek Pharmaceuticals Acquires Optinose in $330 Million Deal to Expand Drug Portfolio (GeneOnline) - "Paratek Pharmaceuticals has finalized the acquisition of Optinose in a deal valued at approximately $330 million. The transaction expands Paratek’s commercial portfolio, adding new products to its lineup and strengthening its position in the pharmaceutical market. The acquisition marks a significant step for Paratek as it integrates Optinose’s assets into its operations. Optinose is known for its innovative approaches to drug delivery, particularly in treating chronic nasal conditions. By acquiring the company, Paratek gains access to these technologies and products, potentially enhancing its ability to address unmet medical needs. The financial details of the agreement place the value of the acquisition at nearly $330 million, underscoring the strategic importance of this move for both companies involved."

M&A • CNS Disorders • Migraine • Pain